Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model

Nikpoor, Amin Reza; Tavakkol‐Afshari, Jalil; Gholizadeh, Zahra; Sadri, Kayvan; Babaei, Mohammad; Chamani, Jamshidkhan; Badiee, Ali; Jalali, Seyed Amir; Jaafari, Mahmoud Reza

doi:10.1016/j.ijpharm.2015.08.048

Cited by 47 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results shown that the accumulation of liposome-encapsulated antibodies in tumors was significantly more than that of free antibodies due to the EPR effect. Also the PEGylated liposomes were more effective in the delivery of antibodies to the tumor place than non-PEGylated liposomes (Nikpoor et al 2015).…”

Section: Nanotechnology In Immunotherapy Of Cancermentioning

confidence: 95%

“…IgG molecules due to their effective functions in immune responses as well as good stability and half-life in the bloodstream are identified as appropriate selection for the development of therapeutic monoclonal antibodies (Weiner et al 2010). But monoclonal antibodies in the treatment of solid tumors have adverse effects in normal tissues and low accumulations at the tumor site (Nikpoor et al 2015). Administrating cytokines, e.g.…”

Section: Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Application of nanostructured drug delivery systems in immunotherapy of cancer: a review

Asadi

Davaran

Panahi

et al. 2016

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The cancer immunotherapy method uses the specificity of the immune system to provide a more effective than more conventional treatments, such as chemotherapy and radiotherapy. Immunotherapy has two main strategies (passive or active) to organize the immune system. Passive strategies use advantage of tumor-hyperpermeable cells, which have enhanced permeability and retention effects. Nanoparticles due to their better accumulation within tissues and cells of the immune system are well suitable for delivery of immune therapies such as vaccines or adjuvants. In this review, we explained application of nanotechnology in immunotherapy of cancer.

show abstract

Section: Nanotechnology In Immunotherapy Of Cancermentioning

confidence: 95%

Section: Immunotherapymentioning

confidence: 99%

Application of nanostructured drug delivery systems in immunotherapy of cancer: a review

Asadi

Davaran

Panahi

et al. 2016

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Where Ao is the initial amount of the drug used, Au is the nonencapsulated drug, W is the amount of lipid material used in the vesicular formulation and Av is the amount of vesicular carrier produced [41].…”

Section: Loading Capacity Encapsulation Efficiency and Vesicle Yieldmentioning

confidence: 99%

Transethosomes and Nanoethosomes: Recent Approach on Transdermal Drug Delivery System

Mishra¹,

Kaur²,

Verma³

et al. 2019

Nanomedicines

View full text Add to dashboard Cite

In the past few decades, an emerging drug delivery system that came into light is transdermal drug delivery system. It has become the talk of the town in the field of drug delivery because of its better and easy accessibility. Though it is one of the attractive routes, transport of drug through the skin has remained a challenge. To overcome the challenge, vesicular system has been adopted so as to have better skin permeation of bioactive agents. Vesicular system like liposome has shown inefficiency to cross the layers of skin. Then transethosomes and nanoethosomes are employed for delivering drug into the deeper layer of skin. Nanoethosomes and transethosomes have same composition that is water, ethanol and phospholipid. Transethosome contains edge activator additionally. Due to the presence of ethanol and edge activator, it displayed enhanced skin permeation. Vesicular system gives a better patient compliance, being a non-invasive method of drug administration. In this chapter, we attempted to provide brief information about methods of preparation, characterization and pharmaceutical uses of nanoethosomes and transethosomes.

show abstract

“…Additionally, only a small fraction of antibodies bind the target of interest. The biodistribution of IVIG outside the bloodstream is poorly understood (Brandtzaeg and Baklien, 1976 ; Wasserman et al, 2012 ; Nikpoor et al, 2015 ), and it is unclear if the concentration of antibody that reaches the site of infection could be sufficient to exert the desired effect.…”

Section: Antibodies For Systemic Administration To Prevent (Relapsingmentioning

confidence: 99%

Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection

et al. 2018

View full text Add to dashboard Cite

Clostridium difficile causes antibiotic- and healthcare-associated diarrhea, which is characterized by a high mortality rate (5–15%) and high recurrence rate of 20% or more. Therapeutic alternatives to antibiotics are urgently needed to improve the overall cure rate. Among these, therapeutic antibodies have shown promising results in clinical studies. Herein, the authors review current monoclonal and polyclonal anti- C. difficile antibodies that have entered the clinical development stage, either for systemic administration or by the oral route. The antibodies can be applied as monotherapy or in combination with standard-of-care to treat an infection with C. difficile or to protect from a recurrence. Bezlotoxumab is the first antibody for secondary prevention of recurrence of C. difficile infection approved by the regulatory agencies in US and Europe. The human monoclonal antibody is administered systemically to patients receiving oral standard-of–care antibiotics. Other antibodies are currently in the clinical pipeline, and some are intended for oral use. They show a good safety profile, high efficacy and low production costs, and can be considered promising therapies of the future. The most promising orally administered drug candidate is a bovine antibody from hyperimmune colostral milk, which is in an advanced clinical development stage. Which antibody will enter the market is dependent on its bioavailability at the site of infection as well as its activity against C. difficile toxins, protection against colonization and possible action on spore formation. The antibody must demonstrate a clear benefit in comparison with other available treatment options to be considered for use by clinicians.

show abstract

Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model

Cited by 47 publications

References 42 publications

Application of nanostructured drug delivery systems in immunotherapy of cancer: a review

Application of nanostructured drug delivery systems in immunotherapy of cancer: a review

Transethosomes and Nanoethosomes: Recent Approach on Transdermal Drug Delivery System

Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection

Contact Info

Product

Resources

About